April 21, 2015

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults study in the New England Journal of Medicine

Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is unknown. In a new study in the New England Journal of Medicine PCV13 has been proven to be effective in preventing vaccine-type, pneumococcal, bacteremic, and non-bacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing community-acquired pneumonia from any cause.

For more information click here.